GlassScriptPhysician profile
Suzanne L Delea
NPI 1841339868
$13,165.43
in general payments reported to CMS, 2019-2025
37 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,674 · 2022: $3,673 · 2023: $3,280 · 2024: $3,130 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,675 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,674.91 |
| Education | $144.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,968.40 | 2021-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,229.02 | 2021-2025 | Otezla, Enbrel, Evenity |
| Ucb, INC. | $1,187.87 | 2021-2024 | Cimzia |
| Astrazeneca Pharmaceuticals LP | $949.19 | 2021-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $656.10 | 2021-2025 | |
| Glaxosmithkline, LLC. | $579.28 | 2021-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $472.52 | 2021-2025 | Tremfya, Simponi Aria |
| Mallinckrodt Hospital Products INC. | $465.18 | 2021-2025 | Acthar |
| Pfizer INC. | $439.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $403.28 | 2021-2024 | Ofev, Cyltezo |
| Radius Health, INC. | $380.55 | 2022-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $302.64 | 2021-2024 | Orencia |
| Lilly USA, LLC | $272.40 | 2021-2023 | Taltz |
| Horizon Therapeutics Plc | $209.83 | 2022-2023 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $181.34 | 2022-2024 | Opsumit, Uptravi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $162.16 | 2021-2023 | Strensiq |
| Ani Pharmaceuticals, INC. | $153.23 | 2022-2024 | Purified Cortrophin Gel |
| Genzyme Corporation | $129.64 | 2023-2024 | |
| Sobi, INC | $115.43 | 2021-2024 | |
| Janssen Scientific Affairs, LLC | $110.15 | 2021 | |
| Fresenius Kabi USA, LLC | $99.97 | 2023-2024 | Idacio |
| Aurinia Pharma U.S., INC. | $98.53 | 2022-2025 | Lupkynis |
| Genentech USA, INC. | $82.97 | 2022-2024 | Actemra, Rituxan |
| Kiniksa Pharmaceuticals, LTD. | $69.95 | 2022-2023 | Arcalyst |
| Pacira Therapeutics, INC. | $66.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.52 | 2024-2025 | |
| Novo Nordisk INC | $46.81 | 2025 | Ozempic |
| Celltrion USA INC. | $44.07 | 2023 | Yuflyma |
| Organon LLC | $40.76 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $37.95 | 2024 | Arcalyst |
| Sandoz INC. | $26.75 | 2025 | Jubbonti |
| Kyowa Kirin, INC. | $25.75 | 2023 | Crysvita |
| Boston Scientific Corporation | $22.93 | 2021 | |
| Arcutis Biotherapeutics, INC. | $22.80 | 2024 | Zoryve |
| Ardelyx, INC. | $18.48 | 2025 | Ibsrela |
| Nevro Corp. | $14.81 | 2022 | |
| Abbott Laboratories | $14.16 | 2023 | Proclaim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Delea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.